Inflammation in nonalcoholic steatohepatitis

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 2, 2011, Pages 189-200

  Harmon, R Christopher ^a   Tiniakos, Dina G ^b   Argo, Curtis K ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

adipokine; adipose tissue; apoptosis; biopsy; cytokine; histology; inflammation; innate immunity; lipotoxicity; liver; macrophage; NASH

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; APOLIPOPROTEIN C3; ARACHIDONATE 15 LIPOXYGENASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTOKERATIN 18; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FATTY ACID; FRUCTOSE; GASTRIC INHIBITORY POLYPEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 4; KRUPPEL LIKE FACTOR 6; LIPID; PIOGLITAZONE; PLACEBO; TAUROURSODEOXYCHOLIC ACID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ACINAR CELL; APOPTOSIS; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FAT CONTENT; HEPATITIS; HEREDITY; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; INTRAABDOMINAL FAT; LIPID DIET; LIPOTOXICITY; LIVER FIBROSIS; LIVER INJURY; LIVING DONOR; METABOLIC SYNDROME X; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATION; OXIDATIVE STRESS; PREVALENCE; REVIEW; SCORING SYSTEM;

ABDOMINAL FAT; ADIPOKINES; ANIMALS; CYTOKINES; FATTY LIVER; FRUCTOSE; GASTROINTESTINAL TRACT; HEPATITIS; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MICE; MUSCLE, SKELETAL; OXIDATIVE STRESS;

EID: 79954498879     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.11.21     Document Type: Review

References (148)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43(2 Suppl. 1), S99-S112 (2006).
2. Yamamoto K, Takada Y, Fujimoto Y et al. Nonalcoholic steatohepatitis in donors for living donor liver transplantation. Transplantation 83(3), 257-262 (2007).
3. Williams CD, Stengel J, Asike MI et al. Prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among largely middle-aged population utilizing ultrasound and liver biopsy. Gastroenterology 140(1), 124-131 (2011).
4. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am. J. Gastroenterol. 97(6), 1496-1500 (2002). (Pubitemid 34664799)
5. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am. J. Gastroenterol. 99(2), 292-298 (2004). (Pubitemid 38279872)
6. Amarapurkar DN, Hashimoto E, Lesmana LA et al. How common is non-alcoholic fatty liver disease in the Asia-Pacifc region and are there local differences? J. Gastroenterol. Hepatol. 22(6), 788-793 (2007). (Pubitemid 46911047)
7. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver Dis. 28(4), 339-350 (2008).
8. Targher G, Bertolini L, Padovani R et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among Type 2 diabetic patients. Diabetes Care 30(5), 1212-1218 (2007). (Pubitemid 46684650)
9. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. (40 Suppl. 1), S5-S10 (2006). (Pubitemid 44309537)
10. FalckYtter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 21(1), 17-26 (2001). (Pubitemid 32240483)
11. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 116(6), 1413-1419 (1999). (Pubitemid 29258890)
12. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 40(Suppl. 1), S11-S16 (2006). (Pubitemid 44309538)
13. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J. Hepatol. 40(4), 578-584 (2004). (Pubitemid 38367778)
14. Schwimmer JB, Celedon MA, Lavine JE et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 136(5), 1585-1592 (2009).
15. Valenti L, Alisi A, Galmozzi E et al. I 148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 52(4), 1274-1280 (2010).
16. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 40(12), 1461-1465 (2008).
17. Kotronen A, Johansson LE, Johansson LM et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 52(6), 1056-1060 (2009).
18. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity J. Lipid Res. 50(10), 2111-2116 (2009).
19. He S, McPaul C, Li JZ et al. A sequence variation (I148M) in PNPLA3 associated with non-alcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285(9), 6706-6715 (2010).
20. Johansson LE, Lindblad U, Larsson CA, Rastam L, Ridderstrale M. Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity Eur. J. Endocrinol. 159(5), 577-583 (2008).
21. Petersen KF, Dufour S, Hariri A et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl. J. Med. 362(12), 1082-1089 (2010).
22. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs H. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 53(2), 467-474 (2010).
23. Miele L, Beale G, Patman G et al. The Kruppel-like factor 6 genotype is associated with fbrosis in nonalcoholic fatty liver disease. Gastroenterology 135(1), 282-291.e1 (2008).
24. Day CP. Genetic and environmental susceptibility to non-alcoholic fatty liver disease. Dig Dis. 28(1), 255-260 (2010).
25. Angulo P. Nonalcoholic fatty liver disease. N Engl. J. Med. 346(16), 1221-1231 (2002).
26. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 21(1), 27-41 (2001). (Pubitemid 32240484)
27. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52(2), 774-788 (2010).
28. Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-ß and NF-κB. Nat Med. 11(2), 183-190 (2005). (Pubitemid 40321354)
29. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 103(6), 1372-1379 (2008). (Pubitemid 351813900)
30. Puri P, Mirshahi F, Cheung O et al. Activation and dysregulation of the unfolded protein response in non-alcoholic fatty liver disease. Gastroenterology 34, 568-576 (2008). (Pubitemid 351173040)
31. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51(5), 1820-1832 (2010).
32. Stickel F, Hellerbrand C Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 59(10), 1303-1307 (2010).
33. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fbrosis in patients with nonalcoholic steatohepatitis. Hepatology 30(6), 1356-1362 (1999).
34. Garcia-Monzon C, Martin-Perez E, Iacono OL et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J. Hepatol. 33(5), 716-724 (2000).
35. Ratziu V, Giral P, Charlotte F et al. Liver fbrosis in overweight patients. Gastroenterology 118(6), 1117-1123 (2000).
36. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37(4), 917-923 (2003). (Pubitemid 36397405)
37. Park KS, Lee YS, Park HW et al. Factors associated or related to with pathological severity of nonalcoholic fatty liver disease. Korean J. Intern. Med. 19(1), 19-26 (2004). (Pubitemid 41237484)
38. Ong JP, Elariny H, Collantes R et al. Predictors of nonalcoholic steatohepatitis and advanced fbrosis in morbidly obese patients. Obes. Surg. 15(3), 310-315 (2005). (Pubitemid 40463594)
39. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fbrosis in nonalcoholic fatty liver disease. Hum. Pathol. 35(2), 196-199 (2004). (Pubitemid 38240902)
40. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fbrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51(2), 371-379 (2009).
41. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 27(6), 1463-1466 (1998). (Pubitemid 28264666)
42. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin. Liver Dis. 13(4), 545-563 (2009).
43. Argo CK, Al-Osaimi AM, Shah NL, Gahring KA, Weltman AL, Caldwell SH. Insulin resistance and deconditioning: further evidence of 'metabolic obesity' in nonobese NASH. Hepatology 52(Suppl. 1), A630 (2010).
44. Farrell GC, Hall PM, George J et al. Fatty Liver Disease: NASH and Related Disorders. Blackwell Publishing, London, UK, 1-319 (2004).
45. Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51(1), 121-129 (2010).
46. Tilg H, Moschen AR. Evolution of infammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52(5), 1836-1846 (2010).
47. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115(5), 1343-1351 (2005). (Pubitemid 40629054)
48. Yu XX, Murray SF, Pandey SK et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42(2), 362-371 (2005). (Pubitemid 41061089)
49. Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J. Lipid Res. 49(11), 2283-2301 (2008).
50. Baranova A, Gowder SJ, Schlauch K et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes. Surg 16(9), 1118-1125 (2006). (Pubitemid 44433145)
51. Younossi ZM, Jarrar M, Nugent C et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg 18(11), 1430-1437 (2008).
52. Musso G, Gambino R, Durazzo M et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42(5), 1175-1183 (2005). (Pubitemid 43112685)
53. Musso G, Gambino R, De Michieli F et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37(4), 909-916 (2003). (Pubitemid 36397404)
54. Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin. Nutr. 25(5), 816-823 (2006). (Pubitemid 44426431)
55. Toshimitsu K, Matsuura B, Ohkubo I et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 23(1), 46-52 (2007). (Pubitemid 44959764)
56. Pickens MK, Yan JS, Ng RK et al. Dietary sucrose is essential to the development of liver injury in the methionine-choline-defcient model of steatohepatitis. J. Lipid Res. 50(10), 2072-2082 (2009).
57. Ackerman Z, Oron-Herman M, Grozovski M et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 45(5), 1012-1018 (2005). (Pubitemid 40628952)
58. Davail S, Rideau N, Bernadet MD, Andre JM, Guy G, Hoo-Paris R. Effects of dietary fructose on liver steatosis in overfed mule ducks. Horm. Metab. Res. 37(1), 32-35 (2005). (Pubitemid 40269449)
59. Ouyang X, Cirillo P, Sautin Y et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol. 48(6), 993-999 (2008).
60. Puri P, Baillie RA, Wiest MM et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46(4), 1081-1090 (2007). (Pubitemid 350144772)
61. Puri P, Wiest MM, Cheung O et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50(6), 1827-1838 (2009).
62. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89(6), 2548-2556 (2004). (Pubitemid 38766330)
63. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol. Sci. 24(6), 276-283 (2003). (Pubitemid 36725002)
64. Miyazaki Y, DeFronzo RA. Visceral fat dominant distribution in male Type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type. Cardiovasc. Diabetol. 8, 44 (2009).
65. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145(5), 2273-2282 (2004). (Pubitemid 38535056)
66. Fisher FM, McTernan PG, Valsamakis G et al. Differences in adiponectin protein expression: effect of fat depots and Type 2 diabetic status. Horm. Metab. Res. 34(11-12), 650-654 (2002). (Pubitemid 36398701)
67. Perrini S, Laviola L, Cignarelli A et al. Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. Diabetologia 51(1), 155-164 (2008). (Pubitemid 350197987)
68. Gastaldelli A, Miyazaki Y, Mahankali A et al. The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 29(10), 2275-2281 (2006). (Pubitemid 44899865)
69. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis. 28(1), 179-185 (2010).
70. Asterholm IW, Scherer PE. Enhanced metabolic fexibility associated with elevated adiponectin levels. Am. J. Pathol. 176(3), 1364-1376 (2010).
71. Motoshima H, Wu X, Sinha MK et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J. Clin. Endocrinol. Metab. 87(12), 5662-5667 (2002). (Pubitemid 36034375)
72. Mori Y, Murakawa Y, Okada K et al. Effect of troglitazone on body fat distribution in Type 2 diabetic patients. Diabetes Care. 22(6), 908-912 (1999). (Pubitemid 29241043)
73. Kawai T, Takei I, Oguma Y et al. Effects of troglitazone on fat distribution in the treatment of male Type 2 diabetes. Metabolism 48(9), 1102-1107 (1999). (Pubitemid 29418278)
74. Hirose H, Kawai T, Yamamoto Y et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with Type 2 diabetes. Metabolism 51(3), 314-317 (2002). (Pubitemid 34232632)
75. Bajaj M, Suraamornkul S, Piper P et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated Type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89(1), 200-206 (2004). (Pubitemid 38183882)
76. Gastaldelli A, Harrison S, Belfort-Aguiar R et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment. Pharmacol. Ther. 32(6), 769-775 (2010).
77. Sabate JM, Jouet P, Harnois F et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes. Surg. 18(4), 371-377 (2008).
78. Miele L, Valenza V, La Torre G et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49 (6), 1877-1887 (2009).
79. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit infammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37(2), 343-350 (2003). (Pubitemid 36152533)
80. Syn WK, Yang L, Chiang DJ et al. Genetic differences in oxidative stress and infammatory responses to diet-induced obesity do not alter liver fbrosis in mice. Liver Int. 29(8), 1262-1272 (2009).
81. Ikura Y, Ohsawa M, Suekane T et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 43(3), 506-514 (2006).
82. Gawrieh S, Opara EC, Koch TR. Oxidative stress in nonalcoholic fatty liver disease: pathogenesis and antioxidant therapies. J. Investig Med. 52(8), 506-514 (2004). (Pubitemid 40105592)
83. Perlemuter G, Davit-Spraul A, Cosson C et al. Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease. Liver Int. 25(5), 946-953 (2005). (Pubitemid 41404014)
84. Kodama Y, Brenner DA. C-Jun N-terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease: multiple roles in multiple steps. Hepatology 49(1), 6-8 (2009).
85. Albano E, Mottaran E, Vidali M et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fbrosis. Gut 54(7), 987-993 (2005). (Pubitemid 40873914)
86. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362(18), 1675-1685 (2010).
87. Brunt EM, Tiniakos DG. Alcoholic and non-alcoholic fatty liver disease. In: Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Odze RD, Goldblum JR, Crawford JM (Eds). Saunders Elsevier, PA, USA, 1087-1114 (2009).
88. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. 5, 145-171 (2010).
89. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94(9), 2467-2474 (1999). (Pubitemid 29420675)
90. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev. Gastroenterol. Hepatol. 7(4), 195-203 (2010).
91. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44(4), 865-873 (2006). (Pubitemid 46489550)
92. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver Dis. 13(4), 511-531 (2009).
93. Rafq N, Bai C, Fang Y et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 7(2), 234-238 (2009).
94. Soderberg C, Stal P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51(2), 595-602 (2010).
95. Brunt EM, Kleiner DE, Wilson LA et al. Portal chronic infammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 49(3), 809-820 (2009).
96. Schwimmer JB, Behling C, Newbury R et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42(3), 641-649 (2005). (Pubitemid 41233657)
97. Nobili V, Marcellini M, Devito R et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 44(2), 458-465 (2006). (Pubitemid 44214885)
98. Carter-Kent C, Yerian LM, Brunt EM et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study Hepatology 50(4), 1113-1120 (2009).
99. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 50(4), 1282-1293 (2009).
100. Rakha EA, Adamson L, Bell E et al. Portal infammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. J. Clin. Pathol. 63(9), 790-795 (2010).
101. Neuschwander-Tetri BA, Clark JM, Bass NM et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52(3), 913-924 (2010).
102. Yip WW, Burt AD. Alcoholic liver disease. Semin. Diagn. Pathol. 23(3-4), 149-160 (2006). (Pubitemid 46176510)
103. Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J. Hepatol. 44(1), 197-208 (2006). (Pubitemid 41772535)
104. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6), 1313-1321 (2005). (Pubitemid 40770284)
105. Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 49(5), 450-465 (2006). (Pubitemid 44631618)
106. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J. Gastroenterol. 16(42), 5286-5296 (2010).
107. Lefkowitch JH, Haythe JH, Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod. Pathol. 15(7), 699-704 (2002). (Pubitemid 34787304)
108. Fotiadu A, Gagalis A, Akriviadis E et al. Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease. Pathol. Int. 60(2), 87-92 (2010).
109. Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors refecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical fndings in younger Asian patients. J. Gastroenterol. Hepatol. 22(4), 491-497 (2007). (Pubitemid 46434984)
110. Stienstra R, Saudale F, Duval C et al. Kupffer cells promote hepatic steatosis via interleukin-1ß-dependent suppression of peroxisome proliferator-activated receptor α activity. Hepatology 51(2), 511-522 (2010).
111. Bieghs V, Wouters K, van Gorp PJ et al. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology 138(7), 2477-2486, 2486.e1-3 (2010).
112. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J. Hepatol. 51(1), 212-223 (2009).
113. Wynn TA, Barron L. Macrophages: master regulators of infammation and fbrosis. Semin. Liver Dis. 30(3), 245-257 (2010).
114. Kang H, Greenson JK, Omo JT et al. Metabolic syndrome is associated with greater histologic severity, higher crbohydrate, and lower fat diet in patients with NAFLD. Am. J. Gastroenterol. (10), 2247-2253 (2006). (Pubitemid 44477551)
115. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum. Pathol. 35(9), 1070-1082 (2004). (Pubitemid 39165338)
116. Yeh M, Brunt EM. Pathology of fatty liver: differential diagnosis of fatty liver disease. Diagn. Histopathol. 14, 586-597 (2008).
117. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 48(2), 670-678 (2008).
118. Valenti L, Fracanzani AL, Fargion S. The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? Semin. Immunopathol. 31(3), 359-369 (2009).
119. Kremer M, Thomas E, Milton RJ, et al. Kupffer cells and interleukin-12 dependent loss of natural killer T cells in hepatosteatosis. Hepatology 51(1), 130-141, (2010).
120. Syn WK, Oo YH, Pereira TA et al.Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology. 51(6), 1998-2007 (2010).
121. Hammerich L, Heymann F, Tacke F. Role of IL-17 and Th17 cells in liver disease. Clin. Dev. Immunol. 2011, 345803 (2011).
122. Oo YH, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. J. Autoimmiunity 34(1), 45-54 (2010).
123. van der Poorten D, Milner KL, Hui J et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 48(2), 449-457 (2008).
124. Suganami T, Ogawa Y Adipose tissue macrophages: their role in adipose tissue remodeling. J. Leukoc. Biol. 88(1), 33-39 (2010).
125. Santoro N, Kursawe R, DAdamo E et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 52(4), 1281-1290 (2010).
126. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade infammation and insulin resistance in human obesity Curr. Pharm. Des. 14(12), 1225-1230 (2008). (Pubitemid 351997835)
127. Saukkonen T, Heikkinen S, Hakkarainen A et al. Association of intramyocellular, intraperitoneal and liver fat with glucose tolerance in severely obese adolescents. Eur. J. Endocrinol. 163(3), 413-419 (2010).
128. McGavock JM, Victor RG, Unger RH, Szczepaniak LS, American College of Physicians and the American Physiological Society Adiposity of the heart, revisited. Ann. Intern. Med. 144(7), 517-524 (2006).
129. Turpin SM, Ryall JG, Southgate R et al. Examination of 'lipotoxicity' in skelet al muscle of high-fat fed and ob/ob mice. J. Physiol. 587(Pt 7), 1593-1605 (2009).
130. Perseghin G, Lattuada G, De Cobelli F et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47(1), 51-58 (2008). (Pubitemid 351171041)
131. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study Hepatology 22(6), 1714-1719 (1995).
132. Uslusoy HS, Nak SG, Gulten M, Biyikli Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J. Gastroenterol. 15(15), 1863-1868 (2009).
133. Kashyap SR, Diab DL, Baker AR et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring) 17(9), 1696-1701 (2009).
134. Drucker DJ. The biology of incretin hormones. Cell. Metab. 3(3), 153-165 (2006).
135. Musso G, Gambino R, Pacini G, De Michieli F, Cassader M. Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. Am. J. Clin. Nutr. 89(2), 558-567 (2009).
136. Jarrar MH, Baranova A, Collantes R et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 27(5), 412-421 (2008).
137. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 134(6), 1641-1654 (2008). (Pubitemid 351615416)
138. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study Hepatology 50(4), 1072-1078 (2009).
139. Diab DL, Yerian L, Schauer P et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin. Gastroenterol. Hepatol. 6(11), 1249-1254 (2008).
140. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fbrosis in the severely obese. Gastroenterology 121(1), 91-100 (2001). (Pubitemid 32591518)
141. Poynard T, Ratziu V, Charlotte F et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 6, 34 (2006).
142. Anty R, Iannelli A, Patouraux S et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment. Pharmacol. Ther. 32(11-12), 1315-1322 (2010).
143. Ulitsky A, Ananthakrishnan AN, Komorowski R et al. A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. Obes. Surg. 20(6), 685-691 (2010).
144. Dufour JF, Oneta CM, Gonvers JJ et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 4(12), 1537-1543 (2006). (Pubitemid 44880031)
145. Beraza N, Malato Y, Vander Borght S et al. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut 57(5), 655-663 (2008). (Pubitemid 351579980)
146. Marra F. Nuclear factor-κB inhibition and nonalcoholic steatohepatitis: infammation as a target for therapy Gut 57(5), 570-571 (2008).
147. Schattenberg JM, Singh R, Wang Y et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43(1), 163-172 (2006). (Pubitemid 43733603)
148. Singh R, Wayn Y, Xiang Y et al. Differential effect of JNK-1 and JNK-2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 49, 87-96 (2009).